keyword
MENU ▼
Read by QxMD icon Read
search

Non-small cell lung cancer surgery

keyword
https://www.readbyqxmd.com/read/29160382/lung-cancer-changes-in-histology-gender-and-age-over-the-last-30-years-in-brazil
#1
Maria Teresa Ruiz Tsukazan, Álvaro Vigo, Vinícius Duval da Silva, Carlos Henrique Barrios, Jayme de Oliveira Rios, José Antônio de Figueiredo Pinto
OBJECTIVE: To describe the trends in tumor histology, gender and age among patients with non-small cell lung cancer (NSCLC) treated with lung resection. The histology of lung cancer has changed in developed countries, and there is still little information available on the topic for developing countries. METHODS: This was a retrospective study of 1,030 patients with NSCLC treated with lung resection between 1986 and 2015 at a university hospital in southern Brazil...
September 2017: Jornal Brasileiro de Pneumologia: Publicaça̋o Oficial da Sociedade Brasileira de Pneumologia e Tisilogia
https://www.readbyqxmd.com/read/29158124/improved-survival-with-increased-time-to-radiation-and-sequential-chemotherapy-after-surgery-for-pn2-non-small-cell-lung-cancer
#2
Karna Sura, Inga S Grills, Charles C Vu, Craig W Stevens, Hong Ye, Thomas M Guerrero
BACKGROUND: Currently, the ideal timing for postoperative radiotherapy (PORT) and chemotherapy is unknown. The present study evaluated their relative timing on overall survival (OS) using the National Cancer Database (NCDB). MATERIALS AND METHODS: The NCDB was queried for patients from 2004 to 2012 with resected non-small-cell lung cancer (NSCLC), pathologically involved N2 (pN2) nodes, and negative margins. All patients underwent adjuvant chemotherapy and external beam radiotherapy...
November 17, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29157203/survival-time-following-resection-of-intracranial-metastases-from-nsclc-development-and-validation-of-a-novel-nomogram
#3
Xiaoyu Ji, Yingjie Zhuang, Xiangye Yin, Qiong Zhan, Xinli Zhou, Xiaohua Liang
BACKGROUND: Brain metastases (BM) from non-small cell lung cancer (NSCLC) are the most frequent intracranial tumors. To identify patients who might benefit from intracranial surgery, we compared the six existing prognostic indexes(PIs) and built a nomogram to predict the survival for NSCLC with BM before they intended to receive total intracranial resection in China. METHODS: First, clinical data of NSCLC presenting with BM were retrospectively reviewed. All of the patients had received total intracranial resection and were randomly distributed to developing cohort and validation cohort by 2:1...
November 21, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29157115/subgroup-analysis-based-on-prognostic-and-predictive-gene-signatures-for-adjuvant-chemotherapy-in-early-stage-non-small-cell-lung-cancer-patients
#4
Hojin Moon, Yuan Zhao, Dustin Pluta, Hongshik Ahn
In treating patients diagnosed with early Stage I non-small-cell lung cancer (NSCLC), doctors must choose surgery alone, Adjuvant Cisplatin-Based Chemotherapy (ACT) alone or both. For patients with resected stages IB to IIIA, clinical trials have shown a survival advantage from 4-15% with the adoption of ACT. However, due to the inherent toxicity of chemotherapy, it is necessary for doctors to identify patients whose chance of success with ACT is sufficient to justify the risks. This research seeks to use gene expression profiling in the development of a statistical decision-making algorithm to identify patients whose survival rates will improve from ACT treatment...
November 20, 2017: Journal of Biopharmaceutical Statistics
https://www.readbyqxmd.com/read/29156014/exhaustive-preoperative-staging-increases-survival-in-resected-adrenal-oligometastatic-non-small-cell-lung-cancer-a-multicentre-study
#5
Julien De Wolf, Jocelyn Bellier, Francoise Lepimpec-Barthes, Francois Tronc, Christophe Peillon, Alain Bernard, Jean-Philippe Le Rochais, Olivier Tiffet, Edouard Sage, Alain Chapelier, Henri Porte
OBJECTIVES: Adrenal oligometastatic non-small-cell lung cancer is rare, and surgical management remains controversial. METHODS: We performed a multicentre, retrospective study from January 2004 to December 2014. The main objective was to evaluate survival in patients who had undergone adrenalectomy after resection of primary lung cancer. Secondary objectives were to determine prognostic, survival and recurrence factors. RESULTS: Fifty-nine patients were included...
October 1, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/29153966/nomogram-to-predict-cause-specific-mortality-in-patients-with-surgically-resected-stage-i-non-small-cell-lung-cancer-a-competing-risk-analysis
#6
Huaqiang Zhou, Yaxiong Zhang, Zeting Qiu, Gang Chen, Shaodong Hong, Xi Chen, Zhonghan Zhang, Yan Huang, Li Zhang
BACKGROUND: The objective of this study was to evaluate the probability of cause-specific death and other causes of death in patients with stage I non-small-cell lung cancer (NSCLC) who underwent surgery. We also built competing risk nomograms to predict the prognosis of patients with NSCLC. PATIENTS AND METHODS: Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. We identified patients who underwent surgery with stage I NSCLC between 2004 and 2013...
October 28, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29153898/the-significance-of-the-pd-l1-expression-in-non-small-cell-lung-cancer-trenchant-double-swords-as-predictive-and-prognostic-markers
#7
REVIEW
Kazuki Takada, Gouji Toyokawa, Fumihiro Shoji, Tatsuro Okamoto, Yoshihiko Maehara
Lung cancer is the leading cause of death due to cancer worldwide. Surgery, chemotherapy, and radiotherapy have been the standard treatment for lung cancer, and targeted molecular therapy has greatly improved the clinical course of patients with non-small-cell lung cancer (NSCLC) harboring driver mutations, such as in epidermal growth factor receptor and anaplastic lymphoma kinase genes. Despite advances in such therapies, the prognosis of patients with NSCLC without driver oncogene mutations remains poor. Immunotherapy targeting programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) has recently been shown to improve the survival in advanced NSCLC...
October 28, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29150179/-therapeutic-strategies-in-patients-undergoing-surgery-for-non-small-cell-lung-cancer-results-of-the-escap-2011-cphg-study-promoted-by-the-french-college-of-general-hospital-respiratory-physicians-cphg
#8
F Pinquié, F Goupil, J-P Oster, A Dixmier, P-A Renault, A Lévy, J-P Mathieu, N Paillot, F C Goutorbe, P Masson, O Molinier, D Debieuvre, M Grivaux
BACKGROUND: The aim of ESCAP-2011-CPHG, promoted by the French College of General Hospital Respiratory Physicians, was to describe therapeutic strategies in lung cancer in the first 2 years after diagnosis, in a real-life setting. This article focuses on patients undergoing surgical management of a non-small cell lung cancer (NSCLC). METHODS: A prospective multicentre study was conducted in 53 French general hospitals. For each patient with lung cancer diagnosed in 2010, a standardised form was completed following each change in treatment strategy up to 2 years after diagnosis...
November 14, 2017: Revue des Maladies Respiratoires
https://www.readbyqxmd.com/read/29139039/genetic-screening-and-molecular-characterization-of-met-alterations-in-non-small-cell-lung-cancer
#9
M Saigi, A McLeer-Florin, E Pros, E Nadal, E Brambilla, M Sanchez-Cespedes
PURPOSE: Aberrant activation of MET as a result of exon 14-skipping (METex14) mutations or gene amplification is an oncogenic mechanism in non-small cell lung carcinoma (NSCLC) and a potential therapeutic target. The purpose of this study was to characterize MET alterations in a cohort of NSCLC patients treated with surgery. METHODS AND PATIENTS: 157 NSCLCs of various histopathologies, including pulmonary sarcomatoid carcinomas (PSC), were tested for MET alterations...
November 14, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29137276/potential-clinical-value-of-pet-ct-in-predicting-occult-nodal-metastasis-in-t1-t2n0m0-lung-cancer-patients-staged-by-pet-ct
#10
Xiang Zhou, Ruohua Chen, Gang Huang, Jianjun Liu
We assessed the clinical value of 2-fluoro-2-deoxyglucose ((18)F-FDG) PET/CT imaging for predicting occult nodal metastasis in non-small cell lung cancer (NSCLC) patients. This retrospective study included 54 patients with T1-2N0M0 NSCLC who had undergone (18)F-FDG PET/CT before surgery. Occult nodal metastasis was detected in 25.9% (14/54) of the patients. Immunohistochemical analysis revealed that increased glucose transporter 1 expression was associated with occult nodal metastasis, but hexokinase 2 expression was not...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29136212/neoadjuvant-and-adjuvant-therapy-for-stage-iii-non-small-cell-lung-cancer
#11
Shun-Ichi Watanabe, Kazuo Nakagawa, Kenji Suzuki, Kazuya Takamochi, Hiroyuki Ito, Jiro Okami, Keiju Aokage, Hisashi Saji, Hiroshige Yoshioka, Yoshitaka Zenke, Tadashi Aoki, Yasuhiro Tsutani, Morihito Okada
The treatments for advanced non-small cell lung cancer (NSCLC) should control both local and microscopic systemic disease, because the 5-year survival of patients with Stage III NSCLC who underwent surgical resection alone has been dismal. One way to improve surgical outcome is the administration of chemotherapy before or after the surgical procedure. During the last two decades, many clinical studies have focused on developing optimal adjuvant or neoadjuvant chemotherapy regimens that can be combined with surgical treatment and/or radiotherapy...
November 9, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29136038/midterm-outcomes-of-single-port-thoracoscopic-surgery-for-major-pulmonary-resection
#12
Kook Nam Han, Hyun Koo Kim, Young Ho Choi
INTRODUCTION: Single-port thoracoscopic surgery has widened the current minimally invasive surgical techniques toward more less invasive procedures in terms of reducing the number of incisions. However, the current status of oncologic outcome with this technique is not well known for lung cancer surgery. The purpose of this study is to evaluate the oncologic outcomes in early stage lung cancer for impact of the survival outcomes with our experience of conversion to a single-port approach from the conventional three-port approach...
2017: PloS One
https://www.readbyqxmd.com/read/29132701/postoperative-outcome-after-pulmonary-surgery-for-non-small-cell-lung-cancer-in-elderly-patients
#13
Deniece D E M A Detillon, Eelco J Veen
BACKGROUND: Lung cancer is the main cause of cancer-related death in the Netherlands. Surgery offers the best potential cure, but lower rates of surgery are recorded for octogenarians because of concerns regarding morbidity and mortality. METHODS: We analyzed the Dutch Lung Surgery Audit database to determine the postoperative outcome of lung cancer resections for patients aged 60 years or more between January 2013 and December 2014. Three groups were compared: patients aged 80 years or more, patients aged 70 to 79 years, and patients aged 60 to 69 years...
November 10, 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/29130448/a-review-on-the-effects-of-current-chemotherapy-drugs-and-natural-agents-in-treating-non-small-cell-lung-cancer
#14
Chih-Yang Huang, Da-Tong Ju, Chih-Fen Chang, P Muralidhar Reddy, Bharath Kumar Velmurugan
Lung cancer is the leading cause of cancer deaths worldwide, and this makes it an attractive disease to review and possibly improve therapeutic treatment options. Surgery, radiation, chemotherapy, targeted treatments, and immunotherapy separate or in combination are commonly used to treat lung cancer. However, these treatment types may cause different side effects, and chemotherapy-based regimens appear to have reached a therapeutic plateau. Hence, effective, better-tolerated treatments are needed to address and hopefully overcome this conundrum...
December 2017: BioMedicine
https://www.readbyqxmd.com/read/29129443/adjuvant-chemotherapy-with-or-without-bevacizumab-in-patients-with-resected-non-small-cell-lung-cancer-e1505-an-open-label-multicentre-randomised-phase-3-trial
#15
Heather A Wakelee, Suzanne E Dahlberg, Steven M Keller, William J Tester, David R Gandara, Stephen L Graziano, Alex A Adjei, Natasha B Leighl, Seena C Aisner, Jan M Rothman, Jyoti D Patel, Mark D Sborov, Sean R McDermott, Roman Perez-Soler, Anne M Traynor, Charles Butts, Tracey Evans, Atif Shafqat, Andrew E Chapman, Samer S Kasbari, Leora Horn, Suresh S Ramalingam, Joan H Schiller
BACKGROUND: Adjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC. We aimed to evaluate the addition of bevacizumab to adjuvant chemotherapy in early-stage resected NSCLC. METHODS: We did an open-label, randomised, phase 3 trial of adult patients (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and who had completely resected stage IB (≥4 cm) to IIIA (defined by the American Joint Committee on Cancer 6th edition) NSCLC...
November 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29125868/local-thoracic-therapy-improve-prognosis-for-stage-iv-non-small-cell-lung-cancer-patients-combined-with-chemotherapy-a-surveillance-epidemiology-and-end-results-database-analysis
#16
Kaitai Liu, Dawei Zheng, GuoDong Xu, Zhennan Du, Shibo Wu
Patients with stage IV non-small cell lung cancer (NSCLC) comprise a heterogeneous group, and the optimal treatment for this group of patients is complex and debatable. We aimed to assess the effect of local thoracic therapy combined with chemotherapy on cancer specific survival (CSS). To evaluate the CSS of four subgroups of patients with stage IV NSCLC according to four different treatment modalities: combined modality of Chemotherapy, Surgery, and Radiation (Chem+Sur+RT), Chemotherapy and Radiation (Chem+RT), Chemotherapy and Surgery (Chem+Sur), and Chemotherapy only (Chem Only) by analyzing the Surveillance, Epidemiology, and End Results (SEER)-registered database...
2017: PloS One
https://www.readbyqxmd.com/read/29125427/the-surgical-treatment-of-metastatic-spine-tumors-within-the-intramedullary-compartment
#17
Ben A Strickland, Ian E McCutcheon, Indro Chakrabarti, Laurence D Rhines, Jeffrey S Weinberg
OBJECTIVE Metastasis to the spinal cord is rare, and optimal management of this disease is unclear. The authors investigated this issue by analyzing the results of surgical treatment of spinal intramedullary metastasis (IM) at a major cancer center. METHODS The authors retrospectively reviewed the medical records of 13 patients who underwent surgery for IM. Patients had renal cell carcinoma (n = 4), breast carcinoma (n = 3), melanoma (n = 2), non-small cell lung cancer (n = 1), sarcoma (n = 1), adenoid cystic carcinoma (n = 1), and cervical cancer (n = 1)...
November 10, 2017: Journal of Neurosurgery. Spine
https://www.readbyqxmd.com/read/29124039/surgical-management-of-stage-iiia-non-small-cell-lung-cancer
#18
REVIEW
Paul E Van Schil, Lawek Berzenji, Suresh K Yogeswaran, Jeroen M Hendriks, Patrick Lauwers
According to the eighth edition of the tumor-node-metastasis classification, stage III non-small cell lung cancer is subdivided into stages IIIA, IIIB, and IIIC. They represent a heterogeneous group of bronchogenic carcinomas with locoregional involvement by extension of the primary tumor and/or ipsilateral or contralateral lymph node involvement. Surgical indications have not been definitely established but, in general, long-term survival is only obtained in those patients in whom a complete resection is obtained...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/29124025/efficacy-of-single-port-video-assisted-thoracoscopic-surgery-lobectomy-compared-with-triple-port-vats-by-propensity-score-matching
#19
Kyung Sub Song, Chang Kwon Park, Jae Bum Kim
Background: In recent years, single-port video-assisted thoracoscopic surgery (VATS) for lobectomy in non-small cell lung cancer (NSCLC) patients has become increasingly common. The objective of this study was to compare the feasibility and safety of single-port and triple-port VATS lobectomy. Methods: A total of 73 patients with NSCLC who underwent VATS lobectomy from December 2011 to August 2016 were retrospectively reviewed, including 47 in the triple-port group and 26 in the single-port group...
October 2017: Korean Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/29119942/18f-faza-pet-ct-in-the-preoperative-evaluation-of-nsclc-comparison-with-18f-fdg-and-immunohistochemistry
#20
Paola Mapelli, Valentino Bettinardi, Federico Fallanca, Elena Incerti, Antonia Compierchio, Francesca Rossetti, Angela Coliva, Annarita Savi, Claudio Doglioni, Giampiero Negri, Luigi Gianolli, Maria Picchio
PURPOSE: To assess the capability of 18F-FAZA PET/CT in identifying intratumoral hypoxic areas in early and locally advanced non-small cell lung cancer (NSCLC) patients and to compare 18F-FAZA PET/CT with 18F-FDG PET/CT and histopathological biomarkers and to investigate whether the assessment of tumour to blood (T/B) and tumour to muscle (T/M) ratios provides comparable information regarding the hypoxic fractions of the tumour. MATERIALS AND METHODS: Seven patients with NSCLC were prospectively enrolled (3 men, 4 women; median age: 71 years; range 63-80)...
November 8, 2017: Current Radiopharmaceuticals
keyword
keyword
10512
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"